Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...
BioSpace

Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the ...

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever ...
Medical Marketing & Media

Rx Rundown: Moderna, Merck, LEO Pharma and more

The Food and Drug Administration granted accelerated approval to Zenbexus, or iberdomide, in combination with daratumumab and ...
BioSpace

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...